We found that CCL20 enhanced the RANKL/OPG ratio by stimulating RANKL expression and secretion and reducing OPG expression and secretion in MDA-MB-231 human breast cancer cells in a dose-dependent manner (Fig. 6a,b). The gene discussed is TNFRSF11B; the disease is breast carcinoma.